Case number 2023-1334
Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Oct 6, 2024 | 0 | NOVARTIS PHARMA AG v. REGENERON PHARMACEUTICALS, INC. [OPINION] [nonprecedential] (0) |
| Aug 6, 2024 | 61 | Submitted after ORAL ARGUMENT to Panel: Prost, Circuit Judge; Reyna, Circuit Judge and Chen, Circuit Judge.Arguing counsel: Mr. William M. Jay for Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC and Mr. Anish R. Desai for Regeneron Pharmaceuticals, Inc.Oral Argument Audio available here. [1023117] [JCP] [Entered: 08/06/2024 01:09 PM] (0) |
| Jun 28, 2024 | 60 | Response to notice of oral argument from Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 06/28/2024 by email. [1014233] [23-1334] [William Jay] [Entered: 06/28/2024 12:04 PM] (1) |
| Jun 24, 2024 | 59 | Response to notice of oral argument from Appellee Regeneron Pharmaceuticals, Inc.. Service: 06/24/2024 by email. [1012731] [23-1334] [Anish Desai] [Entered: 06/24/2024 10:08 AM] (1) |
| Jun 21, 2024 | 58 | NOTICE OF ORAL ARGUMENT. Panel: 2408A. Case scheduled August 6, 2024. Response to Notice of Oral Argument due: 07/05/2024. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [1012454] [MVH] [Entered: 06/21/2024 01:18 PM] (2) |
| May 20, 2024 | 57 | The following additional conflict dates submitted by Anish R. Desai for Regeneron Pharmaceuticals, Inc. have been accepted by the court: 07/08/2024, 07/09/2024. [1005413] [MJL] [Entered: 05/20/2024 04:46 PM] (0) |
| May 16, 2024 | 56 | Notice from Appellee Regeneron Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 05/16/2024 by email. [1004738] [23-1334] [Anish Desai] [Entered: 05/16/2024 05:27 PM] (5) |
| May 8, 2024 | 55 | The following conflict dates requested by Anish R. Desai for Regeneron Pharmaceuticals, Inc. (see Doc. No. [53]) are not accepted at this time: 07/08/2024, 07/09/2024, 07/10/2024, 08/05/2024. Please review the Guidance on Oral Argument Scheduling Conflicts for more information. [1002811] [MJL] [Entered: 05/08/2024 10:57 AM] (0) |
| May 8, 2024 | 54 | The following additional conflict dates submitted by William M. Jay for Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC have been accepted by the court: 07/11/2024, 07/12/2024. [1002810] [MJL] [Entered: 05/08/2024 10:55 AM] (0) |
| May 8, 2024 | 53 | Notice from Appellee Regeneron Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 05/08/2024 by email. [1002738] [23-1334] [Anish Desai] [Entered: 05/08/2024 08:06 AM] (3) |
| May 7, 2024 | 52 | Notice from Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC regarding conflicts with oral argument. Service: 05/07/2024 by email. [1002726] [23-1334] [William Jay] [Entered: 05/07/2024 08:19 PM] (3) |
| Mar 27, 2024 | 51 | The following conflict dates requested by Anish R. Desai for Regeneron Pharmaceuticals, Inc. (see Doc. No. [50]) are not accepted at this time: 06/03/2024, 06/04/2024. Please review the Guidance on Oral Argument Scheduling Conflicts for more information. [993231] [MJL] [Entered: 03/27/2024 08:48 AM] (0) |
| Mar 22, 2024 | 50 | Notice from Appellee Regeneron Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 03/22/2024 by email. [992326] [23-1334] [Anish Desai] [Entered: 03/22/2024 10:30 AM] (4) |
| Mar 19, 2024 | 49 | The following conflict dates requested by William M. Jay for Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC (see Doc. No. [48]) are not accepted at this time: 05/06/2024, 05/07/2024. Please review the Guidance on Oral Argument Scheduling Conflicts for more information. [991444] [MJL] [Entered: 03/19/2024 09:48 AM] (0) |
| Mar 18, 2024 | 48 | Notice from Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC regarding conflicts with oral argument. Service: 03/18/2024 by email. [991309] [23-1334] [William Jay] [Entered: 03/18/2024 02:49 PM] (3) |
| Feb 20, 2024 | 47 | The following conflict dates submitted by William M. Jay for Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC have been accepted by the court: 05/06/2024, 05/07/2024, 05/08/2024, 05/09/2024, 05/10/2024. [985032] [MJL] [Entered: 02/20/2024 03:29 PM] (0) |
| Feb 16, 2024 | 46 | Notice from Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC regarding conflicts with oral argument. Service: 02/16/2024 by email. [984680] [23-1334] [William Jay] [Entered: 02/16/2024 05:02 PM] (4) |
| Nov 9, 2023 | 45 | The following conflict dates submitted by Anish R. Desai for Regeneron Pharmaceuticals, Inc. have been accepted by the court: 01/08/2024, 01/09/2024, 05/06/2024, 05/07/2024, 05/08/2024, 05/09/2024, 05/10/2024, 06/05/2024, 06/06/2024, 06/07/2024. The following conflict dates are not accepted at this time: 01/10/2024, 01/11/2024, 01/12/2024, 06/03/2024, 06/04/2024. [962517] [MJL] [Entered: 11/09/2023 11:23 AM] (0) |
| Nov 9, 2023 | 44 | The following conflict dates submitted by William M. Jay for Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC have been accepted by the court: 03/04/2024, 03/05/2024, 03/06/2024, 03/07/2024, 03/08/2024. [962478] [MJL] [Entered: 11/09/2023 10:29 AM] (0) |
| Nov 8, 2023 | 43 | Notice from Appellee Regeneron Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 11/08/2023 by email. [962204] [23-1334] [Anish Desai] [Entered: 11/08/2023 11:25 AM] (4) |
| Nov 6, 2023 | 42 | 6 paper copies of Doc. No. [37], [34], [26] received from Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. [962003] [VDW] [Entered: 11/07/2023 02:29 PM] (0) |
| Nov 6, 2023 | 41 | Notice from Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC regarding conflicts with oral argument. Service: 11/06/2023 by email. [961784] [23-1334] [William Jay] [Entered: 11/06/2023 06:45 PM] (3) |
| Nov 3, 2023 | 40 | 6 paper copies of Doc. No. [33] received from Appellee Regeneron Pharmaceuticals, Inc.. [961380] [VDW] [Entered: 11/03/2023 03:42 PM] (0) |
| Nov 2, 2023 | 39 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [961009] [KMH] [Entered: 11/02/2023 02:21 PM] (0) |
| Nov 2, 2023 | 38 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [961007] [KMH] [Entered: 11/02/2023 02:19 PM] (1) |
| Oct 10, 2023 | 37 | MODIFIED ENTRY: CONFIDENTIAL APPENDIX FILED by Appellants Novartis Pharma AG and Novartis Pharmaceuticals Corporation. Service: 10/10/2023 by email. [955443]--[Edited 11/02/2023 by KMH - compliance review complete] [William Jay] [Entered: 10/10/2023 07:11 PM] (0) |
| Oct 10, 2023 | 36 | MODIFIED ENTRY: APPENDIX FILED by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 10/10/2023 by email. [955442] --[Edited 11/02/2023 by KMH - compliance review complete] [William Jay] [Entered: 10/10/2023 06:59 PM] (1145) |
| Oct 2, 2023 | 35 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 10/02/2023 by email. [953813] [23-1334] [William Jay] [Entered: 10/02/2023 06:12 PM] (3) |
| Oct 2, 2023 | 34 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 10/02/2023 by email. [953812]--[Edited 10/11/2023 by MMA - Reason: compliance review complete] [William Jay] [Entered: 10/02/2023 06:10 PM] (43) |
| Aug 10, 2023 | 32 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED by Appellee Regeneron Pharmaceuticals, Inc.. Service: 08/10/2023 by email. [942190] --[Edited 08/18/2023 by KMH - compliance review complete] [Anish Desai] [Entered: 08/10/2023 07:20 PM] (80) |
| Aug 10, 2023 | 33 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL RESPONSE BRIEF FILED by Appellee Regeneron Pharmaceuticals, Inc.. Service: 08/10/2023 by email. [942192]--[Edited 08/18/2023 by KMH - compliance review complete] [Anish Desai] [Entered: 08/10/2023 07:21 PM] (0) |
| Aug 9, 2023 | 31 | NOTICE OF NON-COMPLIANCE: The submission of Appellee Regeneron Pharmaceuticals, Inc., Response Brief [27], [28], is not in compliance with the rules of this court (see attached). Compliant document due on 08/16/2023. Service as of this date by the Clerk of Court. [941817] [KMH] [Entered: 08/09/2023 03:12 PM] (2) |
| Aug 8, 2023 | 30 | **TEXT ONLY** ORDER granting motion to extend time to file brief [29] filed by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. The reply brief is due 10/02/2023. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [941474] [JPS] [Entered: 08/08/2023 02:52 PM] (0) |
| Aug 7, 2023 | 29 | MOTION of Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC to extend the time to 10/02/2023 to file brief. Service: 08/07/2023 by email. [941212] [23-1334] [William Jay] [Entered: 08/07/2023 05:39 PM] (8) |
| Jul 26, 2023 | 28 | CONFIDENTIAL RESPONSE BRIEF FILED by Appellee Regeneron Pharmaceuticals, Inc.. Service: 07/26/2023 by email. [938727] [23-1334] This document is non-compliant. See Doc No. [31] [Anish Desai] [Entered: 07/26/2023 06:05 PM] (0) |
| Jul 26, 2023 | 27 | RESPONSE BRIEF FILED by Appellee Regeneron Pharmaceuticals, Inc.. Service: 07/26/2023 by email. (PENDING COMPLIANCE REVIEW) [938726] [23-1334] [Anish Desai] [Entered: 07/26/2023 06:02 PM] (221) |
| Jul 25, 2023 | 26 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL OPENING BRIEF FILED by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 07/25/2023 by email. [938443]--[Edited 08/02/2023 by KMH - compliance review complete] [William Jay] [Entered: 07/25/2023 05:06 PM] (0) |
| Jul 25, 2023 | 25 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 07/25/2023 by email. [938439] --[Edited 08/02/2023 by KMH - compliance review complete] [William Jay] [Entered: 07/25/2023 05:02 PM] (227) |
| Jul 25, 2023 | 24 | ORDER filed granting motion to waive confidentiality requirements [21], but ECF Nos. 20 and 22 are not accepted for filing. Corrected versions of the opening brief, addressing the issues raised above, are due no later than 7 days from the date of entry of this order. (Per Curiam). Service as of this date by the Clerk of Court. [938366] [LMS] [Entered: 07/25/2023 02:15 PM] (2) |
| Jul 13, 2023 | 23 | RESPONSE of Appellee Regeneron Pharmaceuticals, Inc. to Doc No. [21]. Service: 07/13/2023 by email. [936079] [23-1334] [Anish Desai] [Entered: 07/13/2023 12:40 PM] (15) |
| Jul 3, 2023 | 22 | CORRECTED CONFIDENTIAL OPENING BRIEF FILED by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 07/03/2023 by email. [933874] [23-1334] This doument is non-compliant. See Order [24] [William Jay] [Entered: 07/03/2023 03:39 PM] (0) |
| Jul 3, 2023 | 21 | MOTION of Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC to waive confidentiality requirements. Service: 07/03/2023 by email. [933872] [23-1334] [William Jay] [Entered: 07/03/2023 03:35 PM] (40) |
| Jul 3, 2023 | 20 | CORRECTED OPENING BRIEF FILED by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 07/03/2023 by email. [933865] [23-1334] This document is non-compliant. See Order [24] [William Jay] [Entered: 07/03/2023 03:26 PM] (227) |
| Jul 3, 2023 | 19 | Amended Certificate of Interest for Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 07/03/2023 by email. [933857] [23-1334] [William Jay] [Entered: 07/03/2023 03:17 PM] (3) |
| Jun 29, 2023 | 18 | Entry of Appearance for Joshua Weinger as counsel for Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 06/29/2023 by email. [933101] [23-1334] [Joshua Weinger] [Entered: 06/29/2023 10:29 AM] (1) |
| Jun 21, 2023 | 17 | ORDER filed denying [13] the motion to waive the requirements of Federal Circuit Rule 25.1(d)(1) without prejudice to appellants filing a corrected brief or a new motion within 10 days of the date of filing of this order. (see order for further details). Service as of this date by the Clerk of Court. [931353] [LMS] [Entered: 06/21/2023 12:39 PM] (3) |
| Jun 2, 2023 | 16 | ORDER granting motion to extend time to file brief [15] filed by Appellee Regeneron Pharmaceuticals, Inc. The response brief is due 07/26/2023. Service as of this date by the Clerk of Court. [927455] [LMS] [Entered: 06/02/2023 02:28 PM] (2) |
| May 24, 2023 | 15 | MOTION of Appellee Regeneron Pharmaceuticals, Inc. to extend the time to 07/26/2023 to file brief. Service: 05/24/2023 by email. [925734] [23-1334] [Anish Desai] [Entered: 05/24/2023 05:10 PM] (10) |
| May 17, 2023 | 14 | CONFIDENTIAL OPENING BRIEF FILED by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 05/17/2023 by email. (PENDING COMPLIANCE REVIEW) [924232] [23-1334] [William Jay] [Entered: 05/17/2023 11:55 PM] (0) |
| May 17, 2023 | 13 | MOTION of Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC to waive confidentiality requirements. Service: 05/17/2023 by email. [924231] [23-1334] [William Jay] [Entered: 05/17/2023 11:52 PM] (32) |
| May 17, 2023 | 12 | OPENING BRIEF FILED by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 05/17/2023 by email. (PENDING COMPLIANCE REVIEW) [924230] [23-1334] [William Jay] [Entered: 05/17/2023 11:26 PM] (227) |
| May 17, 2023 | 11 | Notice of Related Case Information for Appellants Novartis Pharma AG, Novartis Technology LLC and Novartis Pharmaceuticals Corporation. Service: 05/17/2023 by email. [924123] [23-1334] [William Jay] [Entered: 05/17/2023 02:02 PM] (3) |
| Apr 3, 2023 | 10 | **TEXT ONLY** ORDER granting motion to extend time to file brief [9] filed by Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. The opening brief is due 05/17/2023. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [914074] [KMH] [Entered: 04/03/2023 03:29 PM] (0) |
| Mar 29, 2023 | 9 | MOTION of Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC to extend the time to 05/17/2023 to file brief. Service: 03/29/2023 by email. [913182] [23-1334] [William Jay] [Entered: 03/29/2023 07:27 PM] (8) |
| Feb 16, 2023 | 8 | Certified list received. Service: 02/14/2023 by email. Refer to Fed. Cir. R. 31 for calculating brief deadlines from service of the certified list. [904626] [KMH] [Entered: 02/16/2023 09:42 AM] (0) |
| Jan 19, 2023 | 7 | Docketing Statement for the Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 01/19/2023 by email. [898221] [23-1334] [William Jay] [Entered: 01/19/2023 08:24 PM] (2) |
| Jan 19, 2023 | 6 | Certificate of Interest for Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 01/19/2023 by email. [898220] [23-1334] [William Jay] [Entered: 01/19/2023 08:23 PM] (3) |
| Jan 19, 2023 | 5 | Entry of Appearance for William M. Jay; William James; Elizabeth Holland, Gerard J. Cedrone as counsel for Appellants Novartis Pharma AG, Novartis Pharmaceuticals Corporation and Novartis Technology LLC. Service: 01/19/2023 by email. [898219] [23-1334] [William Jay] [Entered: 01/19/2023 08:19 PM] (2) |
| Jan 19, 2023 | 4 | Docketing Statement for the Appellee Regeneron Pharmaceuticals, Inc.. Service: 01/19/2023 by email. [898144] [23-1334] [Anish Desai] [Entered: 01/19/2023 04:26 PM] (2) |
| Jan 19, 2023 | 3 | Certificate of Interest for Appellee Regeneron Pharmaceuticals, Inc.. Service: 01/19/2023 by email. [898141] [23-1334] [Anish Desai] [Entered: 01/19/2023 04:25 PM] (3) |
| Jan 19, 2023 | 2 | Entry of Appearance for Anish R. Desai; Elizabeth S. Weiswasser; Adam B. Banks; Christopher Pepe; Priyata Patel as counsel for Appellee Regeneron Pharmaceuticals, Inc.. Service: 01/19/2023 by email. [898140] [23-1334] [Anish Desai] [Entered: 01/19/2023 04:24 PM] (2) |
| Jan 5, 2023 | 1 | Appeal docketed. Received: 12/23/2022. [894837] Entry of Appearance due 01/19/2023. Certificate of Interest is due on 01/19/2023. Docketing Statement due 01/19/2023. Certified List due on 02/14/2023. [KMH] [Entered: 01/05/2023 11:54 AM] (0) |
